"One of the powers of our technique is that you can take the same molecule and, instead of inserting an alpha-emitting isotope, insert an alpha-imaging isotope. We're actually able to use imaging to determine which patients have the target expressed in high concentration and most likely to respond to the therapy."
John Valliant, founder and CEO, Fusion Pharmaceuticals Inc., which has raised $25 million from a series A round to support development of targeted alpha-particle radiotherapeutics to treat cancer. Lead program FPX-01 is an antibody-targeted radiotherapy that seeks out insulin-like growth factor-1 receptor, or IGF-1R, a biomarker of resistance that's present on nearly all types of solid tumors

"China's medical landscape is changing and improving every day. People like to criticize it and say it's not mature, that you can't find good health care in China, but that isn't true. You just have to know where to find it and that is gradually becoming easier."
Sigal Atzmon, president at Medix Group, an international medical consultancy with a regional base in Hong Kong

"Mouse models are always questionable regarding their validity; in particular whether they really represent what happens in humans. Using RNA-Seq, we got a complete picture of all the genes activated during infection and disease in mice. As these matched well with what is seen in humans, this provides some level of validation of the model; in other words, what we find in mice is likely to be true in humans."
Andreas Suhrbier, professor and leader of the Inflammation Biology Group at the QIMR Berghofer Medical Research Institute, on an Australian study by researchers at the QIMR Berghofer Medical Research Institute in Brisbane showing that a specific immune system proteinase, granzyme A, promotes arthritic inflammation in mice infected with chikungunya virus (CHIKV). It also suggested granzyme A could serve as a potential target for new drugs to treat CHIKV infection and related viral arthritides in humans